PredicineWES+™
Use
PredicineWES+™ offers genome-wide molecular insights through liquid biopsy exome sequencing. This test provides unrivaled resolution of structural variations, rearrangements, and exon duplicates. It is designed for biomarker analysis in clinical trials, treatment monitoring, and the acquisition of drug resistance with a single blood draw. The combination of whole exome sequencing (WES) with targeted deep sequencing of 600 key cancer genes allows unprecedented genomic insights, supporting comprehensive biomarker analysis across different cancer types.
Special Instructions
Not provided.
Limitations
PredicineWES+™ results are dependent on the quality and amount of input DNA. Lower tumor fractions in samples may impact sensitivity. Certain genomic regions may not be covered in its entirety due to technical limitations of Next Generation Sequencing (NGS). The test is not to be used for diagnostic procedures without validation in accordance with appropriate guidelines.
Methodology
NGS (WES)
Biomarkers
Result Turnaround Time
10 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2-5 mL
Minimum Volume
Not provided